Genmab A/S (GMAB) Stock Price, News & Analysis

Company Overview

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates. Its technologies have contributed to medicines such as DARZALEX (daratumumab) for multiple myeloma, Kesimpta (ofatumumab) for relapsing forms of multiple sclerosis, and Tivdak (tisotumab vedotin) for certain patients with cervical cancer. Genmab and AbbVie also developed EPKINLY (epcoritamab-bysp), a treatment for certain types of B-cell lymphoma. Commercial rights and responsibilities for these products vary among Genmab and its collaborators.

Founded in 1999, Genmab serves international markets through research, development and commercial partnerships spanning North America, Europe and other regions. The company maintains operations in Denmark, the United States and additional locations supporting its global development activities. Genmab is led by Dr. Jan van de Winkel, who serves as President and Chief Executive Officer and has been associated with the company’s scientific and operational development for many years.

Key Stats

• Today's Range: $35.37 to $35.91
• 50-Day Range: $28.52 to $35.57
• 52-Week Range: $23.62 to $35.91
• Volume: 5.15 million shs
• Average Volume: 2.00 million shs
• Market Capitalization: $22.26 billion
• P/E Ratio: 28.09
• Dividend Yield: N/A
• Price Target: $39.50
• Consensus Rating: Moderate Buy

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 80% of companies evaluated by MarketBeat, and ranked 94th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Genmab A/S has a consensus price target of $39.50, representing about 10.3% upside from its current price of $35.83.

Amount of Analyst Coverage

Genmab A/S has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 29.75%

Earnings Growth

Earnings for Genmab A/S are expected to grow by 29.75% in the coming year, from $1.21 to $1.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 28.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 28.22, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.68.

Price to Earnings Growth Ratio

Genmab A/S has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 3.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genmab A/S has recently decreased by 27.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.29

News Sentiment

Genmab A/S has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Genmab A/S this week, compared to 6 articles on an average week.

Search Interest

11 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.

MarketBeat Follows

6 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.54% of the stock of Genmab A/S is held by insiders.

Percentage Held by Institutions

7.07% of the stock of Genmab A/S is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GMAB
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: N/A
• Employees: 3,029
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Genmab A/S: $39.50
• High Price Target: $43.00
• Low Price Target: $32.00
• Potential Upside/Downside: +10.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.27
• Trailing P/E Ratio: 28.09
• Forward P/E Ratio: 29.48
• P/E Growth: 1.92
• Net Income: $963 million
• Net Margins: 19.08%
• Pretax Margin: 21.93%
• Return on Equity: 14.89%
• Return on Assets: 7.73%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 2.46
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $4.13 billion
• Price / Sales: 5.39
• Cash Flow: $1.62 per share
• Price / Cash Flow: 21.97
• Book Value: $9.10 per share
• Price / Book: 3.92

Miscellaneous

• Outstanding Shares: 624,059,000
• Free Float: 614,448,000
• Market Cap: $22.26 billion
• Optionable: Optionable
• Beta: 0.84